The injectable route does offer better bioavailability since it bypasses first-pass metabolism in the gut and liver, but the total weekly dose from a compounded tirzepatide injection remains well below what studies have used to demonstrate significant metabolic effects
We teach them to sacrifice
See also: GLP-1 Guides | Peptide Guides Key Takeaway See your GLP-1 options in about 2 minutes
Administration and Safety TB-500 Administration: Commonly given via subcutaneous injection Typically used in 46 week cycles Initial phase: 23 injections per week Maintenance phase: Reduced frequency as directed by a healthcare provider BPC-157 Administration: Can be taken via subcutaneous injection, localized injection, or oral capsule (for gut health) Dosage varies depending on injury type and severity Can be used for short-term injury recovery or longer cycles for chronic conditions Safety Note: Both TB-500 and BPC-157 should be used under medical supervision
The FDA similarly removed it from its shortage list on February 21, 2025, but this time, it designated off-ramps for production of compounded types right off the bat: Technically, 503A pharmacies have until April 22 to quit making semaglutide drugs, while 503B facilities have until May 22
Find Out If Wegovy is Clinically Suitable Clinician-led medical assessment Personalised dosing and nutrition support Ongoing clinical monitoring throughout treatment What Is Wegovy and How Does It Work